Reported 1 day ago
Edgewise Therapeutics (EWTX) is highlighted as one of the top stocks that could potentially double investors' money due to its strong pipeline in treating muscular disorders and a solid financial position. With significant upside potential and growing hedge fund interest, the clinical-stage biotech company focuses on innovative therapies like EDG-5506 and EDG-7500. Analysts see exciting opportunities ahead, especially following positive early clinical data, placing EWTX as the 6th most promising stock among those poised for substantial returns.
Source: YAHOO